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Abstract
The misfolding and aggregation of proteins is often implicated in the development and progression of degenerative diseases. Heat shock proteins (HSPs), such as the ubiquitously
expressed Type II Hsp40 molecular chaperone, DNAJB6, assist in protein folding and disaggregation. Historically, mutations within the DNAJB6 G/F domain have been associated
with Limb-Girdle Muscular Dystrophy type 1D, now referred to as LGMDD1, a dominantly
inherited degenerative disease. Recently, novel mutations within the J domain of DNAJB6
have been reported in patients with LGMDD1. Since novel myopathy-causing mutations in
the Hsp40 J domain have yet to be characterized and both the function of DNAJB6 in skeletal muscle and the clients of this chaperone are unknown, we set out to assess the effect of
these mutations on chaperone function using the genetically tractable yeast system. The
essential yeast Type II Hsp40, Sis1, is homologous to DNAJB6 and is involved in the propagation of yeast prions. Using phenotypic, biochemical, and functional assays we found that
homologous mutations in the Sis1 J domain differentially alter the processing of specific
yeast prion strains, as well as a non-prion substrate. These data suggest that the newlyidentified mutations in the J domain of DNAJB6 cause aberrant chaperone function that
leads to the pathogenesis in LGMDD1.

Introduction
Molecular chaperones preserve protein homeostasis [1]. A deficient chaperone network may
lead to protein misfolding and aggregation often associated with protein conformational disorders such as Alzheimer’s Disease, Charcot-Marie-Tooth disease, distal hereditary motor neuropathies, and Limb Girdle Muscular Dystrophy, among others [2,3]. Limb Girdle Muscular
Dystrophy type 1D (LGMD1D), more recently termed LGMDD1 [4], is a disease characterized
by proximal muscle weakness with moderate progression mediated by defective chaperone
function [5]. Historically, dominantly inherited disease-associated mutations in the type II
Hsp40 co-chaperone DNAJB6 have been found within a 12 amino acid region known as the
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G/F domain [6–11]. Recently, three novel pathogenic mutations associated with LGMDD1
have been identified within the J domain of DNAJB6 [12,13].
Since molecular chaperones are highly conserved from yeast to mammals, we used a yeast
model system to study these disease-associated mutations [14–16]. The essential yeast Type II
Hsp40, Sis1, is homologous to DNAJB6 and plays an important role in yeast for the propagation of two prions, [RNQ+] and [PSI+] [17–22]. Prions in yeast are epigenetic elements that
form when the prion proteins form amyloid aggregates. These prion protein aggregates are
propagated by fragmentation into propagons, which are then passed on to progeny during
mitosis [14]. Somewhat counterintuitively, chaperones not only promote prion propagation in
yeast, but are essential for it [14,23–26]. At the heart of this chaperone-mediated process is the
Hsp40 Sis1, with the interaction between Hsp40 and Hsp70 chaperones being crucial for prion
propagation in yeast [24,27–32]. When chaperone function is defective, prion propagation is
impaired [17,33–36]. Thus, the loss of prion propagation provides a read-out for chaperone
dysfunction in yeast.
Homologous LGMDD1-associated mutations of the DNAJB6 G/F domain impair the propagation of various yeast prion strains when expressed in Sis1 [37]. We were inspired by this
model to assess the effect of homologous J domain mutants in Sis1 on chaperone function.
Fortunately, the yeast model system allows for a wide array of phenotypic, biochemical, and
functional assays to assess the effect of these mutations on chaperone function [14,38]. As
such, we assessed the ability of the disease-associated mutant chaperone to process two specific
clients of Sis1, Sup35 and Rnq1, which form the prion elements [PSI+] and [RNQ+], respectively. In addition, we performed functional assays with a non-prion client of the yeast chaperone machinery, firefly luciferase (FFL) [39]. In conjunction, these assays elucidated nuances in
client processing due to disease-associated mutations in a manner that would not be possible
by assessing a single client protein or using a limited number of assays.
Here, we present evidence that disease-associated mutations in the J domain cause functional defects that differentially impair processing of native proteins in a client and conformer
specific manner. Our work suggests that mutations in the J domain are responsible for altered
protein processing and, potentially, disease pathogenesis.

Materials and methods
Protein sequence alignment structure modeling
Protein sequences for DNAJB6b orthologs were found on UniProt and subsequently aligned
to homologous disease-causing J domain mutations in Sis1. Sequences were visualized using
BioEdit [40] with multiple sequences aligned through the use of ClustalW2 [40–42]. Mutant
DNAJB6b structures were generated through the use of using I-TASSER [43–45] and visualized using PyMOL [46]. Structural comparisons and protein threading of variants to wild-type
protein structures was performed using wild-type Sis1 (PBD: 4RWU) [21].

Yeast cultures, transformations and treatments
All experiments were performed in derivates of 74-D694 (ade1-14 his3-Δ200 leu2-3,112 trp1289 ura3-52). Yeast strains are [PSI+], [psi-], [RNQ+], or [rnq-], kindly gifted by S. Liebman
[47,48] and J. Weissman [49]. Yeast were cultured using YPD (1% yeast extract, 2% peptone,
2% dextrose), 1/4 YPD (0.25% yeast extract, 2% peptone, 2% dextrose) or synthetic defined
(SD) media (0.67% yeast nitrogen base without amino acids, 2% dextrose) lacking specific
amino acids using standard techniques. In order to study the function of sis1 mutants in the
absence of wild type SIS1, previously described plasmid shuffle strains carrying pRS316-SIS1
[37] were transformed with pRS314 [50] carrying sis1 mutants. We selected for colonies that
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lost wild type SIS1 through plasmid shuffle on plates containing 5-fluoroorotic acid (5-FOA).
Plasmid transformations were performed by the PEG/LiOAC method [51]. Plasmid
pRS316-Sis1 was a kind gift from E. Craig [17,18]. Plasmid 316-GPD-Lux was a kind gift from
J. Weissman [52]. Other plasmids are described below and were constructed using standard
molecular techniques. For curing of prion strains, yeast were passaged twice on 3mM guanidine hydrochloride (GdnHCl) plates, then grown on complete media without GdnHCl for use
in assays.

Plasmid construction
Oligonucleotides used for site-directed mutagenesis are listed in S1 Table. Using pRS314-SIS1,
the J domain LGMDD1 mutations were created by site-directed mutagenesis using the Agilent
QuikChange II XL Site-Directed Mutagenesis Kit, as per manufacturer’s instructions along
with the following oligonucleotides: 1890 and 1891 (S49V), 1892 and 1893 (E53A), 1894 and
1895 (N56L). Primer sequences were generated using Agilent’s online primer design program.
Mutagenesis was confirmed by sequencing the entire coding region of SIS1.

Yeast phenotypic assays
For yeast spottings, cultures were grown overnight in selective media. Cultures were pelleted,
washed, and suspended in water to an optical density of 0.1. The normalized yeast solutions
were pipetted into a 96-well plate, and serial dilutions (1:5) were made using a multichannel
pipette. Yeast were spotted onto plates using an ethanol-sterilized 48-pin replicator. To monitor cell growth or the [PSI+] status of yeast cells with the spread plate assay, overnight cultures
were normalized by A600, serially diluted 5-fold, and spotted on the indicated media. [PSI+]
status was assessed by colony color on large 145mm plates in rich 1⁄4 YPD media. Plates were
incubated for 5 days at 30˚C followed by overnight incubation at 4˚C for additional color
development.

Protein analysis
For boiled gel assays, yeast strains were cultured overnight. Cells were lysed with glass beads in
buffer (25mM Tris-HCl pH7.5, 100mM NaCl, 1mM EDTA, protease inhibitors) and precleared at 6,000 rpm for 1 minute at 4˚C. Protein concentration of cell lysates was normalized
using a Bradford assay and mixed with SDS-Page sample buffer (200mM Tris-HCl pH 6.8, 4%
SDS, 0.4% bromophenol blue, 40% glycerol). Samples remained un-boiled and were loaded on
a 12% polyacrylamide gel and run under constant current of 110V until the dye front migrated
halfway through the resolving gel. The current was then stopped and, with the assembled gel
remaining intact within the glass plates, they were sealed in plastic and boiled upright for
15mins in a 95–100˚C water bath. After boiling, gels were removed from the plastic cover and
were reinserted in the SDS-PAGE apparatus, where voltage was re-applied until the dye
migrated to the bottom of the gel. SDS-PAGE was followed by standard western blotting with
Sup35, Sis1, and Pgk1 antibodies. Sedimentation analysis for Rnq1 was performed as previously described [37,53]. Semi-denaturing agarose gel electrophoresis (SDD-AGE) for [PSI+]
was performed as previously described [37,54].

Luciferase refolding
Luciferase refolding assays were performed as previously described [55]. To monitor the ability
of Sis1 to enhance refolding of luciferase in vivo, [PSI+] or [rnq-] yeast strains were transformed with the plasmid pRS316-GPD-Lux. Cultures were grown overnight in selective media
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and back diluted to an optical density of 0.3 in 8mL plastic culture tubes. Subsequently, cyclohexamide was added to a final concentration of 10ug/mL. Treated samples were then subjected
to heat shock at 42˚C for 22 minutes. Meanwhile, control samples were plated in 98-well clear
bottom plates and kept at 30˚C. After heat shock, 200ul of each sample was plated in triplicate
on 98-well clear bottom plates. All cultures were allowed to recover at 30˚C. Luminometer
readings were taken at 30, 60, 90 and, 120 minutes. For data analysis, each triplicate was averaged. 2way ANOVA was performed using GraphPad Prism version 8.1.1 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com.

Statistical methods
Data are reported as the means SEM of at least three independent experiments. Comparisons
between multiple groups were performed by one-way analysis of variance test (ANOVA). For
comparison between two groups, the paired t-test was used. In all cases, p<0.05 was considered significant. GraphPad Prism 8.1.1 software (GraphPad Software) was used for analysis.

Antibodies and reagents
The following antibodies were used for Western Blots: rabbit anti-Sup35, dilution 1:1000
(True lab); rabbit anti-Sis1, dilution 1:5000 (Cosmo Bio, COP-080051); rabbit anti- Rnq1-11,
dilution 1:2500 (True lab); mouse anti-Pgk1, dilution 1:2000 (Abcam, ab113687). For the firefly luciferase refolding assay, D-Luciferin (Sigma, L9504) was used as a substrate.

Results
Homologous mutations in the Sis1 J domain are conserved and potentially
alter J domain and G/F domain interaction
Recently, novel mutations located within a 7 amino acid region of the DNAJB6 J domain have
been reported to cause dominant distal myopathy [12,13]. These variants were identified in
five different families presenting with both distal and proximal muscle weakness. Initial studies
examined these variants in patient tissue and cell culture studies in an attempt to elucidate
whether these mutations lead to functional defects in DNAJB6’s anti-aggregation activity.
From these studies, the recently identified DNAJB6 variants DNAJB6-A50V, DNAJB6-E54A
and DNAJB6-S57L have been categorized as pathogenic, likely pathogenic, and variant of
unknown significance, respectively [12].
To further examine the effect of these disease-associated variants on myopathy, we performed protein threading to identify homologous mutations in the yeast Hsp40 Sis1. Our comparative modeling identified homologous J domain mutations in Sis1 to be Sis1-S49V
(homologous to DNAJB6-A50V), Sis1-E53A (homologous to DNAJB6-E54A), and Sis1-N56L
(homologous to DNAJB6-S57L) (Fig 1A). In addition, our structural model recapitulates the
observation that mutations in the J domain have the potential to disrupt important intramolecular interactions previously shown to stabilize the interface between the G/F and J domains
(Fig 1B) [12,21].

Homologous mutations in the J domain of Sis1 differentially impair [PSI+]
prion propagation
To assess the implications of these disease-causing variants on chaperone function, we turned
to prion propagation models in yeast. Such models have been used extensively to study chaperones and understand the deleterious effects of disease-associated mutations on protein folding
[56–62]. In yeast, prions are naturally occurring, self-propagating protein structures that
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Fig 1. Novel LGMDD1 disease-associated mutations were identified in the J-domain of DNAJB6. (A) Amino acid
sequence comparison of DNAJB6 and orthologs, including the yeast Hsp40, Sis1, aligned using ClustlW2. (B) Protein
structure identifying homologous LGMDD1-associated mutations in the Sis1 J domain.
https://doi.org/10.1371/journal.pone.0234207.g001

require chaperone networks for their efficient propagation [14]. Defects in chaperone function
disrupt this process and, therefore, prion propagation [27,33–36,53,63]. In order to ask
whether these disease variants disrupt client processing, we studied two known Sis1 substrates:
the translation termination factor Sup35, which can aggregate to form the [PSI+] prion, and
Rnq1, which can aggregate to form the [RNQ+] prion [14,29].
In an effort to understand the effect of homologous J domain mutations on [PSI+] prion
propagation we performed experiments utilizing strains harboring the ade1-14 allele that has a
premature stop codon in the ADE1 open reading frame [14]. When Sup35 misfolds and aggregates in the [PSI+] state, nonsense suppression of the premature stop codon in ade1-14 occurs
and the adenine biosynthesis pathway is completed. Thus, [PSI+] colonies are white in color
and can grow on media lacking adenine. Conversely, if cells are [psi-], adenine biosynthesis is
incomplete, resulting in cells that are unable to grow in media lacking adenine and an accumulation of red pigment in cells grown on rich media. This colorimetric phenotypic assay has
been utilized to demonstrate the effect of LGMDD1-causing G/F domain mutations on [PSI+]
propagation [37]. Here, we make use of four different [PSI+] strains (weak, strong, Sc37, and
Sc4) [47,64]. Each prion strain is a different self-propagating conformation of the same protein
sequence and they are differentiated by the strength of the nonsense suppression phenotype
and stability of their mitotic inheritance [49,64,65,66]. Yeast containing ade1-14 that propagate
stronger [PSI+] strains (strong and Sc4) display higher nonsense suppression and are lighter in
color. Yeast propagating weaker [PSI+] strains (weak and Sc37) are darker in color due to
decreased nonsense suppression (better translation termination). Sis1 is required for yeast viability [67]. Therefore, to perform these experiments, we used sis1Δ yeast (covered by a plasmid
expressing Sis1) propagating different [PSI+] strains (weak, strong, Sc37, and Sc4) and replaced
SIS1 with homologous LGMDD1 mutant SIS1 constructs or wild-type SIS1 (as a control) (Fig
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Fig 2. Homologous LGMDD1-associated mutations in the Hsp40 Sis1 differentially impair propagation of [PSI+] strains. (A) Yeast 74-D694 sis1Δ
[PSI+] strains expressing wild-type SIS1 or mutated SIS1 constructs were serially diluted 5-fold and spotted onto 1/4 YPD media and SD-Ade to monitor
nonsense suppression of the ade1-14 allele (n = 3). (B) [PSI+] colonies expressing the indicated constructs were isolated, grown in liquid YPD overnight,
and plated on large 1/4 YPD spread-plates. An average of 626 colonies were counted and scored for strong [PSI+], weak [PSI+] or [psi-]/very weak
phenotype. Data were collected from three separate biological replicates. (C) Representative western blot of yeast sis1Δ [PSI+] strains expressing wildtype SIS1 or mutated sis1 constructs. Cells were lysed and subjected to a boiled gel assay in order to display the amount of aggregated and monomeric
Sup35 with antibodies against Sup35. Pgk1 is shown as a loading control. While we observed some reproducible differences in the percentage of
monomeric Sup35 as compared to wild-type, we found these differences were not statistically significant. Standard protein markers are inappropriate for
this particular assay and therefore are not shown (n = 4–7). All samples were analyzed under the same experimental conditions.
https://doi.org/10.1371/journal.pone.0234207.g002

2A). In doing so, we observed viability was not affected in these strains expressing the
mutants.
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Interestingly, we found that expression of Sis1-S49V in the weak [PSI+] strain, but not the
Sc37 [PSI+] strain, altered the weak strain phenotype, as indicated by the lighter color on rich
media and robust growth in selective media as compared to wild-type (Fig 2A). In comparison
to the other J domain mutants, the stronger nonsense suppression phenotype we observed is
unique to expression of Sis1-S49V in the weak [PSI+] strain. This suggests altered processing
of Sup35 by Sis1-S49V occurs with conformational specificity. We questioned whether expression of Sis1-S49V could have altered the conformation of Sup35 in weak [PSI+] in a manner
that leads to the propagation of a strong [PSI+] strain. Intrigued by this result, we introduced
pRS316-Sis1 (wildtype) to this strain and re-assessed its [PSI+] phenotype (S1 Fig). We found
this reverted the phenotype and was comparable to wild-type controls, suggesting that
Sis1-S49V expression does not alter the [PSI+] strain. Previous work demonstrated that a
shortage of cytosolic Sis1 may lead to more efficient transmission of propagons to daughter
cells thus “strengthening” the prion phenotype [68]. Thus, we hypothesize this may occur
when Sis1-S49V is expressed in a weak [PSI+] strain.
This assay also showed that the expression of either Sis1-E53A or Sis1-N56L altered the
propagation of the weaker [PSI+] strains (weak and Sc37), albeit in a different manner and to
varying degrees. This is indicated by the phenotypic change towards a red color (less nonsense
suppression) on rich media and lack of growth on media lacking adenine (Fig 2A). Similarly,
when we introduced a wild type copy of SIS1 to these phenotypically red strains, we identified
a partial rescue of the weak [PSI+] phenotype (S1 Fig) indicating these Sis1 mutants, although
phenotypically [psi-], result in propagation of cryptic [PSI+] propagons [69].
Complementarily, we used this assay quantitatively by phenotypically scoring large numbers of colonies on rich media spread plates (Fig 2B). This assay allows for a more detailed
understanding of any changes in [PSI+] propagation. We scored colony color as light pink
(strong [PSI+]), dark pink (weak [PSI+]) or red (very weak [PSI+] or [psi-]) in yeast expressing
wild type Sis1 or the homologous LGMDD1 mutants. Indeed, through this assay we found that
the expression of these mutants phenotypically altered prion propagation and identified a phenotypic variation that was not previously appreciated in the spotting assay. We observed a
wider range of phenotypic variation in the weaker strains than in the stronger [PSI+] strains,
which rarely convert to a weaker phenotype [70,71]. However, an increase in the amount of
darker pink colonies was observed when Sis1-S49V and Sis1-N56L were expressed in the
stronger [PSI+] strains. Similar results were observed when Sis1-E53A and Sis1-N56L were
expressed in the Sc4 [PSI+] strain (Fig 2B).
To further explore these results with respect to the solubility of the prion protein, we performed boiled gel assays to examine the relative levels of aggregated and monomeric Sup35.
This assay consists of loading unboiled samples onto a sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) gel. By doing so, non-denatured aggregates are too large to
enter the resolving gel while monomeric Sup35 readily enters the gel due to its size and lack of
aggregation. Halfway through electrophoresis, the gel itself is boiled and then run again, which
allows previously aggregated protein to enter the resolving gel. The boiled gel assay provides a
clear separation of monomeric and aggregated species of Sup35 and is easily detected through
subsequent western blots [72]. In order to examine the distribution of Sup35 between the
aggregated and monomeric forms, we grew cultures from colonies representative of the phenotypic distribution observed in our spread plate assay.
Expressing homologous J domain mutations in the strong or Sc4 [PSI+] strains did not alter
Sup35 distribution nor phenotype significantly (Fig 2C). Interestingly, the distribution of
Sup35 between monomer and aggregate does not always correlate to phenotype in the weaker
[PSI+] strains (many replicates of these assays were performed to verify reproducibility). Of
note, we previously described a chaperone mutant that demonstrated differences in the ability
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to relate SDS-resistant or small protein aggregates to phenotype [69]. Moreover, we found that
expressing Sis1-S49V in the weak [PSI+] strain led to Sup35 being found mostly in the aggregated state (Fig 2C), coinciding with our phenotypic assay. With regards to expression of
Sis1-E53A in the weak [PSI+] strain, we were surprised to find little Sup35 in the monomeric
fraction, while the expression of Sis1-N56L results in most of the Sup35 in the monomeric
fraction. Interestingly, expressing Sis1-S49V, Sis1-E53A or Sis1-N56L in the Sc37 [PSI+] strain
showed a reproducible yet not statistically significant increase in monomeric Sup35 while
maintaining a modest level of aggregated Sup35. Thus, there are differences with respect to the
interaction between the Sis1 mutants and Sup35 in the weaker [PSI+] strains and how propagons and large aggregates correlate to phenotype.

Homologous mutations in the J domain of Sis1 differentially impair
[RNQ+] prion propagation
We then asked whether mutations in the Sis1 J domain would also affect another known client
of Sis1, the [RNQ+] prion. In a manner similar to that of the previous experiments, we utilized
various [RNQ+] prion strains (rnq-, low, and very high) and expressed each of our Sis1
mutants. Here, we observed reduced growth when Sis1-S49V was expressed in [psi-] strains
that we did not observe in the same yeast strains harboring the [PSI+] prion. Thus, we performed spottings (using 5-fold serial dilutions) and confirmed that expression of Sis1-S49V,
but not Sis1-E53A or Sis1-N56L, resulted in a growth defect (Fig 3A). This effect was only
observed when wild-type Sis1 was removed through plasmid shuffle and occurred when
Sis1-S49V was expressed in either [RNQ+] or [rnq-] strains. This indicated the defect in growth
was independent of [RNQ+] and it was possibly impacted by the loss of [PSI+]. Because Sis1 is
essential for yeast growth, mutations in Sis1 have been shown to affect viability [20,67,73,74].
Unlike the nonsense suppression assay that discerns [PSI+] strains, strains of the [RNQ+]
prion are characterized by the rate at which they induce the formation of [PSI+], ranging from
low to very high rates [72–78]. Therefore, we performed two different biochemical assays to
assess [RNQ+] propagation. First, we performed a sedimentation assay [72] which consists of
separating the soluble and insoluble protein fractions using ultracentrifugation to assay the relative solubility of Rnq1. These fractions are subjected to SDS-Page and probed with an antibody specific to Rnq1. We performed this assay using two [RNQ+] strains, low [RNQ+] and
very high [RNQ+]. Using this assay, we identified a defect in [RNQ+] propagation when
Sis1-S49V is expressed in both low [RNQ+] and very high [RNQ+] strains (Fig 3B). In comparison, there is only a slight change in Rnq1 solubility when Sis1-E53A or Sis1-N56L are
expressed, indicating that J domain variants differentially impair processing of client conformers, albeit not completely.
Furthermore, while the sedimentation assay allows us to detect pelletable aggregates, these
aggregates differ in their SDS sensitivity. In an effort to elucidate whether Rnq1 aggregate size
or SDS resistance was altered by expression of the mutants, we performed a semi-denaturing
detergent agarose gel electrophoresis (SDD-AGE) (Fig 3C). This assay allows for the visualization of SDS-resistant aggregates such as aggregated prion conformers [79]. Strikingly, we
observed a dramatic loss of SDS-resistant Rnq1 aggregates in the low [RNQ+] and very high
[RNQ+] strains when Sis1-S49V was expressed. We also observed a slight reduction in SDSresistant Rnq1 aggregates in low [RNQ+] strains expressing Sis1-E53A, while low [RNQ+]
strains expressing Sis1-N56L appeared unaffected. In addition, very high [RNQ+] strains
expressing Sis1-E53A or Sis1-N56L showed a decreased in SDS-resistant Rnq1 aggregates.
Altogether, these biochemical assays present varying degrees of altered [RNQ+] propagation
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Fig 3. Homologous LGMDD1-associated mutations in the J domain of Sis1 differentially impair propagation of [RNQ+]. (A) Yeast sis1Δ cells harboring the
indicated constructs and propagating low [RNQ+], very high [RNQ+] or [rnq-] were serially diluted 5-fold and spotted onto media in order to express the indicated SIS1
constructs and select for either loss of wild-type Sis1 (-Sis1) or co-expression of wild-type Sis1 (+Sis1). Cells were also spotted on rich media (YPD) as a control for
overall growth (n = 3). (B) Sedimentation assay to separate Rnq1 into soluble and insoluble fractions with expression of the indicated constructs (n = 6). Total (T),
soluble (S) and insoluble (I) fractions were subjected to SDS-PAGE and western blot probing for Rnq1. (C) SDD-AGE assay for the indicated constructs in low [RNQ+]
and very high [RNQ+] strains (n = 4–6). All samples were analyzed under the same experimental conditions.
https://doi.org/10.1371/journal.pone.0234207.g003

that occur in a conformer-specific manner when disease-associated J domain mutants are
expressed in these strains.

Disruption in prion propagation is due to a defect in substrate refolding
We observed different degrees of alteration in prion propagation due to the expression of the
homologous LGMDD1 mutations in the J domain, which vary depending on the client and its
conformation. To further understand the effect of these disease-associated mutations, we
assessed how they impact protein folding of a non-prion substrate in vivo. Thus, we utilized
the well-established firefly luciferase (FFL) refolding assay [52,55] (Fig 4). FFL is a non-prion
substrate of the Hsp40/Hsp70/Hsp104 chaperone machinery and is denatured in cells by heat
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Fig 4. A homologous LGMDD1-associated mutant in Sis1 exhibits impaired substrate refolding. (A) The capability
for refolding luciferase was measured in Sc37 [PSI+] sis1Δ yeast strains harboring the indicated construct along with a
plasmid expressing firefly luciferase (FFL). Yeast were normalized, treated with cycloheximide and subjected to heat
shock at 42˚C for 22 minutes, followed by recovery at 30˚C. Luminescence was measured at the indicated timepoints
during recovery and normalized to luminescence of samples without heat shock treatment. The results represent the
amount of luciferase refolding plotted as the percentage of recovery and represented as mean SEM (n = 6). Each
triplicate was averaged, (two-way ANOVA was performed; �� p indicates a significant difference in Sis1-S49V FFL
refolding relative to WT (p = 0.002) at the indicated timepoint; ��� p indicates a significant difference in Sis1-S49V FFL
refolding relative to WT at the indicated timepoint (p<0.0001)). All samples were analyzed under the same
experimental conditions.
https://doi.org/10.1371/journal.pone.0234207.g004

shock. When FFL misfolds and aggregates it requires the Hsp40/Hsp70/Hsp104 chaperone
machinery to efficiently refold. Since Hsp104 is required for efficient refolding of FFL, we used
a hsp104Δ strain expressing FFL as a negative control. We observed a significant defect in FFL
refolding when Sis1-S49V was expressed in either a [PSI+] [RNQ+] (Fig 4) or [psi-] [rnq-]
strain (S2A Fig), but not when other J domain variants are expressed. Of note, we did not
observe a decrease in Sis1-S49V steady-state levels when this construct was expressed in Sc37
[PSI+] strains (S3 Fig). We subjected other known G/F domain mutants expressed in a chimeric protein where the G/F domain of Sis1 is replaced by that of DNAJB6, referred to as SDSS
[37], to this assay and saw no significant differences in luciferase refolding as compared to wild
type (S2B Fig). Hence, these results highlight the importance of substrate recognition–both
with the client itself, as well as conformer specificity. Most importantly, these findings emphasize the distinction of assessing native chaperone clients as these mutants displayed varying
degrees of altered prion propagation in our assays. Given this specificity, care should be taken
when using certain assays, or a limited number of them, when trying to understand and confirm whether a potentially pathogenic chaperone variant is disease-causing or not.

Stability of a mutated Hsp40 chaperone is rescued by expression of the
[PSI+] prion
While assessing the effect of the J domain LGMDD1 mutations on [RNQ+] propagation we
identified a growth defect that only occurred with expression of the Sis1-S49V variant (Fig
3A). Interestingly, we observed this defect when Sis1-S49V was expressed in [RNQ+] [psi-]
strains, but not when expressed in [PSI+] strains (Figs 2A and 3A). Because SIS1 is essential
[20,67,73,74], we were curious whether this growth defect was due to any change in steadystate expression levels. We assessed steady state Sis1 levels by western blot (Fig 5A) and found
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Fig 5. The LGMDD1-associated J-domain mutation Sis1-S49V has reduced steady state levels in the absence of
[PSI+]. (A) Representative western blot showing expression of the indicated constructs in [rnq-], low [RNQ+], and very
high [RNQ+] strains. (B) Results represent the quantified protein levels of Fig 5A displayed as their ratio relative to
WT. (C) Representative western blot of strong [PSI+] sis1Δ yeast expressing the indicated construct (left). The specified
strong [PSI+] and Sc37 [PSI+] strains expressing the indicated constructs were passaged twice on 3mM guanidine
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hydrochloride (GdnHCl) (cured), then grown on complete media without GdnHCl and lysed for SDS-PAGE followed
by western blot (right). Pgk1 served as a loading control. (D) Results represent the quantified protein levels of Fig 5C
displayed as their ratio relative to WT. For all Western Blot analyses, intensities were quantified and plotted as the
mean SEM (n = 3). Independent experiments indicating a significant difference in Sis1 expression levels relative to WT
(paired t-test; n.s. nonsignificant; � p<0.05; �� p<0.01; ��� p<0.001). All samples were analyzed under the same
experimental conditions.
https://doi.org/10.1371/journal.pone.0234207.g005

a significant decrease in the level of Sis1-S49V in various [rnq-] and [RNQ+] strains (Fig 5B).
We hypothesize that this decrease in steady-state levels is responsible for the growth defect.
To confirm this decrease is due to a lack of [PSI+] presence, we set out to recapitulate this
phenomenon by curing [PSI+] strains of its prion form. Curing of [PSI+] was performed by
growth on media containing guanidine hydrochloride (GdnHCl), which inactivates the
ATPase activity of Hsp104 and hinders the replication of [PSI+] seeds [80]. After curing both a
strong [PSI+] and a Sc37 [PSI+] strain (each expressing Sis1-S49V) we performed western blots
(Fig 5C) and identified a significant decrease in Sis1 steady-state levels (Fig 5D). This decrease
was not observed with expression of wild type Sis1 nor the other LGMDD1 J domain variants.
The decrease in steady-state levels recapitulates what we observed in [psi-] strains expressing
Sis1-S49V (Fig 5A and 5B). This striking result suggests the Sis1 client, Sup35, in its aggregated
and [PSI+]-propagating form, interacts with this particular Hsp40 mutant in a way that stabilizes the steady-state level of Sis1-S49V. Of note, this decrease in Sis1 steady-state levels has not
been observed in the context of LGMDD1-associated mutations found in the G/F domain.
This interesting finding is the first known instance wherein a potentially unstable mutant
chaperone is stabilized by the presence of a specific client protein in its aggregated form.

Discussion
LGMDD1 is a myopathy historically characterized by mutations within the G/F domain of the
chaperone DNAJB6 [6–9,11]. Here we used the yeast model system, a homologous chaperone,
and native chaperone clients to demonstrate that recently reported mutations in the J domain
of DNAJB6 alter canonical chaperone function. Specifically, expression of homologous disease-associated mutations in the yeast Hsp40, Sis1, identified defects in prion propagation to
varying degrees depending on the disease-associated variant, the client protein and its conformation, as well as a significant defect in refolding of a non-prion client protein. We conclude
these mutations in the J domain of Sis1 lead to aberrant chaperone function, altered protein
homeostasis, and potentially drive a variety of defects in chaperone machinery which may contribute to pathogenesis.
The function and interaction of the various Hsp40 domains has been a topic of interest for
many years [20,21,81–86]. Surprisingly, colleagues identified LGMDD1 patients with novel
variants in the J domain of DNAJB6, a disease previously characterized by mutations in the G/
F domain [12,13]. As previously mentioned, LGMDD1 disease-associated mutations in the G/
F domain have been found to impair the processing of specific client conformers. These findings highlighted the G/F domain as having an important role in substrate regulation and
conformer selectivity [37]. By contrast, the J domain of Sis1 has a known role in regulating
Hsp70 ATPase activity [87].
Here we demonstrate a novel finding by which disease-associated missense mutations in
the J domain of an Hsp40 result in the chaperone having client and conformer specificity.
Strikingly, this fits with previous structural studies which have highlighted the importance of
the intramolecular interaction between the J and G/F domains [21]. Specifically, a particular
amino acid, E50, in the Sis1 J domain has been shown to interact with the EEVD(HSP70)
motif, an interaction required for both chaperones to partner in protein refolding [21].
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Moreover, this key amino acid (E50) forms a salt bridge with R73 which is found in the Sis1 G/
F domain. We and others [12,21] believe this interaction is crucial and of functional importance for the stability and interaction between both domains and, ultimately, the interaction
between Hsp40 and Hsp70.
In the context of the LGMDD1-associated mutants found in the J domain, all variants
appear to affect prion propagation to varying degrees depending on client and conformation
specificity. Notably, the homologous Sis1-S49V variant appears to have the most deleterious
effect on the chaperone machinery and its function, probably due to its proximity to the E50:
R73 salt bridge. This would also explain why only Sis1-S49V presented with defective substrate
refolding in our luciferase refolding assay. Overall, we hypothesize that the steric hindrance
caused by these missense mutations may obstruct the intramolecular interaction or communication between the J and G/F domains. Moreover, these findings support the idea that it may
be the interaction between these two domains that is crucial for the specificity and processing
of Hsp40 client proteins.
By assessing the propagation of various Sis1 clients, we found that there are differences in
prion propagation, but that propagation is not completely abolished by expression of these
mutants. When compared to LGMDD1-associated mutations in the G/F domain, for example,
we observe variants in the G/F domain to have a stronger effect on prion propagation in certain assays, oftentimes demonstrating complete loss of prion propagation [37]. As such,
although these disease-associated mutations in the J domain disrupt prion processing and protein refolding, they do so in a manner that is slightly different from that of G/F domain
mutants.
Given the limited knowledge of the clients of DNAJB6 in skeletal muscle and its role in disease, we hypothesize, as we did for the G/F domain mutations, that distinct variants may be
associated with different levels of disease severity due to impairment of Hsp40 function to
varying degrees, or in different ways. Nonetheless, we are cautious to imply that a more drastic
loss-of-propagation effect would correlate with or be causative of a more severe disease pathogenesis, as we have observed different degrees of aberrant chaperone function in the context of
these disease-associated variants that are greatly dependent on client and conformation specificity. It is not uncommon for LGMDD1-associated mutations to have an effect in some but
not all assays or when assaying specific client proteins [12,37]. Moreover, as we continue to
understand and classify disease-associated variants as pathogenic, we should consider how variable clinical outcomes and disease severity may be influenced by factors such as variable
expressivity and sex influences [11]. Given these considerations, there is a need for simple
models, such as the yeast system, by which we can understand if and how identified genetic
variants affect chaperone function in order to better understand variable clinical outcomes
within LGMDD1. Currently, we can only show that there are differences in adequate client
processing and refolding although, undoubtedly, further in vitro studies are required to further
elucidate the mechanistic cause of these functional defects and how they translate to
pathogenesis.
Lastly, we identified a novel phenomenon by which a mutated Hsp40, Sis1-S49V, appears
to have a decreased steady state level of protein expression. This is, to our knowledge, the first
known instance where steady-state expression of a chaperone is dependent on stabilization by
a known substrate. Although serendipitous, this finding not only highlights an important function of chaperone-substrate interaction, but also hints at an additional role that specific substrates might play in chaperone function and protein homeostasis overall. Indeed, there is still
much to be learned about co-chaperones, their function, interactions between themselves and
with clients, and their role in disease pathogenesis.
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Supporting information
S1 Table. Oligonucleotides used in this study.
(TIF)
S1 Fig. Novel LGMDD1 J-domain mutations in Sis1 differentially impair propagation of
[PSI+] strains and are rescued by expression of an additional WT-Sis1 copy. (A) sis1Δ
[PSI+] strains expressing a single copy of wild-type or mutated SIS1, and strains expressing an
additional copy of wild-type SIS1 (+WT) were spotted onto YPD media (n = 3). All spottings,
minus the top (labeled [psi-]) are weak [PSI+] strains expressing the indicated constructs.
(TIF)
S2 Fig. Sis1-S49V exhibits impaired substrate refolding while G/F domain mutants do not.
(A) the capability for refolding luciferase was measured in [rnq-] sis1Δ yeast strains harboring
the indicated construct along with a plasmid expressing luciferase. (B) same as in A, but in
Sc37 [PSI+] strains expressing wild-type or the mutated chimeric construct SDSS constructs
instead of Sis1. Yeast were normalized, treated with cycloheximide and subjected to heat shock
at 42˚C for 22 minutes, followed by recovery at 30˚C. Luminescence was measured at the indicated timepoints during recovery and normalized to luminescence of samples without heat
shock treatment. The amount of luciferase refolding is plotted as percentage of recovery and
represented as mean SEM (n = 6).
(TIF)
S3 Fig. Sis1-S49V, does not show decreased steady-state levels when expressed in Sc37
[PSI+] strain. (A) Representative western blot showing expression of Sis1 in Sc37 [PSI+] sis1Δ
yeast strains harboring the indicated construct (n = 3). Pgk1 is shown as a loading control. All
samples were analyzed under the same experimental conditions.
(TIF)
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